SciELO - Scientific Electronic Library Online

 
vol.37 número 3Importancia del examen médico preventivo para el diagnóstico precoz de enfermedad renal en Uruguay.: Programa Nacional de Salud Renal índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Links relacionados

Compartilhar


Archivos de Medicina Interna

versão impressa ISSN 0250-3816versão On-line ISSN 1688-423X

Resumo

CAMEJO, Natalia et al. Trastuzumab-induced cardiotoxicity in uruguayan patients   with HER positive breast cancer. Arch. Med Int [online]. 2015, vol.37, n. 3, pp.109-113. ISSN 0250-3816.

ABSTRACT: Objective: To evaluate the frequency and severity of Trastuzumab-induced cardiotoxicity in HER2 positive breast cancer (BC) patients assisted in Oncologic Services  of the Hospital de Clínicas and Asociación Española Primera en Salud. Methods: Retrospective observational study of HER2 positive BC patients from Hospital de Clínicas and Asociación Española under systemic therapy with Trastuzumab (TTZ) from January 2007 to December 2013. Results: The study included 69 patients, most were early BC, mean age was 50,1 years . 27% of the patients developed cardiotoxicity and 26 % of them developed symptomatic heart failure. All patients received adequate medical treatment and the most instances were reversible Conclusions: The frequency of cardiotoxicity observed in the study was 27% (IC 95 %: 16,27; 38,8). With the limitations of the study, it can verify reported similarities with other populations, oscillating frequency between 3.7 and 34%. However, the proportion of patients who had symptomatic heart failure (7%) was  higher than that reported in the literatura wich is 4%.  Cardiotoxicity was reversible in most patients.

Palavras-chave : Breast cancer HER positive; trastuzumab; cardiotoxicity.

        · resumo em Espanhol     · texto em Espanhol

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons